Pharming Group to report third quarter 2025 financial results and provide business update on November 6

Rhea-AI Summary

Pharming Group (Euronext: PHARM / Nasdaq: PHAR) will report preliminary unaudited Q3 2025 financial results and provide a business update on Thursday, November 6, 2025.

Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET / 07:30 ET. Investors must register in advance for the conference call or webcast; dial-in attendees will receive a unique PIN and only dial-in participants can ask questions. The webcast will be available on the company’s Investors/Financial Documents page and a replay will be posted shortly after the event.

Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025.

Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET.

To participate in the conference call or to watch the live webcast, please register in advance using the links below.

Conference call registration:
https://register-conf.media-server.com/register/BI1b6a1a63294c427f91ab7b24a7c6484b

Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Please note, the Company will only take questions from dial-in attendees.

Webcast registration:
https://edge.media-server.com/mmc/p/vb724dzx

The webcast will also be accessible on the Pharming website at Investors/Financial Documents, and a replay will be available shortly after the event.

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Attachment

• Pharming Group to report 3Q25 results_EN_23OCT25

FAQ

When will Pharming (PHARM) report Q3 2025 results?

Pharming will report preliminary unaudited Q3 2025 results on November 6, 2025.

What time is the Pharming Q3 2025 conference call and webcast?

The management call and webcast are scheduled for 13:30 CET / 07:30 ET on November 6, 2025.

How can investors join the Pharming Q3 2025 webcast or conference call?

Investors must register in advance via the provided conference call and webcast registration links to receive dial-in details and a PIN.

Can non-dial-in viewers ask questions during the Pharming Q3 2025 event?

No; the company will only take questions from dial-in attendees.

Where will the Pharming Q3 2025 webcast be posted after the event?

The webcast and a replay will be available on Pharming’s Investors/Financial Documents webpage.

Are the Q3 2025 financial results from Pharming final or preliminary?

The results to be reported on November 6 are described as preliminary (unaudited).